Literature DB >> 2504084

How many myocardial infarctions should we rule out?

R L Wears1, S Li, J D Hernandez, R C Luten, D J Vukich.   

Abstract

We used computer simulation to estimate the consequences of four admitting strategies (coronary care unit, intermediate care unit, routine ward care, or outpatient follow-up) on cost, outcome, admission threshold probabilities, and false-positive admission rates for patients with acute myocardial infarction. At virtually any probability of acute myocardial infarction, replacing more intensive by less intensive strategies saved money but increased mortality and decreased life expectancy. Therefore, choices among strategies may be made by using the most effective strategy for progressively lower and lower risk patients until the additional cost per additional life saved reaches a cutoff value; then, a less expensive strategy is selected. With sample cutoff values of $1 and $2 million per life saved, the marginal threshold admission probabilities were: (table; see text) These results imply that the acceptable proportion of false-positive admissions may be as high as 70% to 80%; lower rates could indicate excessively restrictive admitting policies. Clinicians may be operating closer to the optimal decision point than has previously been asserted.

Entities:  

Mesh:

Year:  1989        PMID: 2504084     DOI: 10.1016/s0196-0644(89)80460-3

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  3 in total

1.  Acute chest pain of uncertain etiology, the short and long view.

Authors:  Frans J Th Wackers
Journal:  J Nucl Cardiol       Date:  2012-04       Impact factor: 5.952

2.  The safety and effectiveness of minor injuries telemedicine.

Authors:  J R Benger; S M Noble; J Coast; J M Kendall
Journal:  Emerg Med J       Date:  2004-07       Impact factor: 2.740

3.  Direct hospital costs of chest pain patients attending the emergency department: a retrospective study.

Authors:  Jakob L Forberg; Louise S Henriksen; Lars Edenbrandt; Ulf Ekelund
Journal:  BMC Emerg Med       Date:  2006-05-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.